Antonio de Arriba Muñoz1,2, Vanesa Cancela Muñiz3, José Juan Alcón Saez4, Anunciación Beisti5, Enrique Llovet6, José Ignacio Labarta Aizpún7,8. 1. Paediatric Endocrinology, Hospital Universitario Miguel Servet, Zaragoza, Spain. adearriba@salud.aragon.es. 2. Instituto de Investigación Sanitaria Aragón, Zaragoza, Spain. adearriba@salud.aragon.es. 3. Paediatric Endocrinology, Hospital Universitario de Donostia, San Sebastian, Spain. 4. Paediatric Endocrinology. Paediatrics and Obstetrics-Gynaecology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain. 5. Paediatric Endocrinology, Fundación Hospital de Calahorra, Calahorra, La Rioja, Spain. 6. Head of Biometry, Syntax for Science, Palma, Spain. 7. Paediatric Endocrinology, Hospital Universitario Miguel Servet, Zaragoza, Spain. 8. Instituto de Investigación Sanitaria Aragón, Zaragoza, Spain.
Abstract
PURPOSE: Adherence to growth hormone (GH) treatment impacts clinical outcomes. The aim of this study is to assess the impact of adherence to rhGH treatment (2 years) on auxological outcomes. METHODS: Multicentric, retrospective observational study in rhGH-naïve GHD/SGA children treated with Saizen® during ≥2 years. Growth response was assessed by evaluating the change in height standard deviation score (ΔH SDS) and the index of responsiveness (IoR). Adherence was monitored using EasyPod™ Connect device. RESULTS: A total of 110 patients (3 Spanish centers) were evaluable (GHD n = 76, SGA n = 34). Adherence was 95.6 and 93.9% (year 1, 2). SGA and GHD children showed an increase of 0.6 cm/year and 1.1 cm/year for each 10% adherence modification. Lower adherence was observed in patients with lower pretreatment height velocity (HV) and in patients whose parents had a lower level of education. A positive correlation between index of responsiveness (IoR) during the first and second years with HV SDS during the second year and between IoR2 and adherence (year 1, 2) was observed. The frequency of patients with HV > 1 SD was higher (p = 0.025) among patients with adherence >90%. The best model to predict the height gain(cm) reaching an adjusted R squared of 0.489 involved percentage of adherence, Tanner stage, pretreatment HV, dose of rhGH, and whether the treatment was initiated before or after puberty. CONCLUSIONS: Adherence during the first 2 years of response was very high >90% and showed a negative association with age, pretreatment HV and treatment duration and a positive correlation with the level of parent education.
PURPOSE: Adherence to growth hormone (GH) treatment impacts clinical outcomes. The aim of this study is to assess the impact of adherence to rhGH treatment (2 years) on auxological outcomes. METHODS: Multicentric, retrospective observational study in rhGH-naïve GHD/SGA children treated with Saizen® during ≥2 years. Growth response was assessed by evaluating the change in height standard deviation score (ΔH SDS) and the index of responsiveness (IoR). Adherence was monitored using EasyPod™ Connect device. RESULTS: A total of 110 patients (3 Spanish centers) were evaluable (GHD n = 76, SGA n = 34). Adherence was 95.6 and 93.9% (year 1, 2). SGA and GHD children showed an increase of 0.6 cm/year and 1.1 cm/year for each 10% adherence modification. Lower adherence was observed in patients with lower pretreatment height velocity (HV) and in patients whose parents had a lower level of education. A positive correlation between index of responsiveness (IoR) during the first and second years with HV SDS during the second year and between IoR2 and adherence (year 1, 2) was observed. The frequency of patients with HV > 1 SD was higher (p = 0.025) among patients with adherence >90%. The best model to predict the height gain(cm) reaching an adjusted R squared of 0.489 involved percentage of adherence, Tanner stage, pretreatment HV, dose of rhGH, and whether the treatment was initiated before or after puberty. CONCLUSIONS: Adherence during the first 2 years of response was very high >90% and showed a negative association with age, pretreatment HV and treatment duration and a positive correlation with the level of parent education.
Authors: E Schönau; F Westermann; F Rauch; A Stabrey; G Wassmer; E Keller; J Brämswig; W F Blum Journal: Eur J Endocrinol Date: 2001-01 Impact factor: 6.664
Authors: R R Kapoor; S A Burke; S E Sparrow; I A Hughes; D B Dunger; K K Ong; C L Acerini Journal: Arch Dis Child Date: 2007-09-03 Impact factor: 3.791
Authors: J M Wit; M B Ranke; K Albertsson-Wikland; A Carrascosa; R G Rosenfeld; S Van Buuren; B Kristrom; E Schoenau; L Audi; A C S Hokken-Koelega; P Bang; H Jung; W F Blum; L A Silverman; P Cohen; S Cianfarani; C Deal; P E Clayton; L de Graaff; J Dahlgren; J Kleintjens; M Roelants Journal: Horm Res Paediatr Date: 2013-05-28 Impact factor: 2.852
Authors: Wayne S Cutfield; José G B Derraik; Alistair J Gunn; Kyle Reid; Theresa Delany; Elizabeth Robinson; Paul L Hofman Journal: PLoS One Date: 2011-01-31 Impact factor: 3.240
Authors: Özge Besci; İbrahim Mert Erbaş; Tuncay Küme; Kübra Yüksek Acinikli; Ayhan Abacı; Ece Böber; Korcan Demir Journal: J Clin Res Pediatr Endocrinol Date: 2021-12-06
Authors: Sergio Cervera-Torres; Francisco José Núñez-Benjumea; Antonio de Arriba Muñoz; Irene Alice Chicchi Giglioli; Luis Fernández-Luque Journal: BMC Med Inform Decis Mak Date: 2022-08-13 Impact factor: 3.298